Sandy Srinivas, MD, Stanford University Medical Center

Articles by Sandy Srinivas, MD, Stanford University Medical Center

Dr Srinivas on the Role of Lutetium Lu 177 Vipivotide Tetraxetan in mCRPC

BySandy Srinivas, MD, Stanford University Medical Center

September 19th 2024

Sandy Srinivas, MD, discusses the role of lutetium Lu 177 vipivotide tetraxetan for patients with metastatic castration-resistant prostate cancer.

Prostate Cancer Management: Future Directions in Care

ByAlicia Morgans, MD, MPH, FASCO,Matthew Smith, MD, PhD,Sandy Srinivas, MD, Stanford University Medical Center,Scott T. Tagawa, MD, MS,Evan Y. Yu, MD

May 25th 2022

Closing out their discussion on the management of prostate cancer, panelists consider remaining unmet needs and future directions in care.

Results of the VISION Trial and Real-World Use of 177Lu-PSMA-617 in mCRPC

ByAlicia Morgans, MD, MPH, FASCO,Matthew Smith, MD, PhD,Sandy Srinivas, MD, Stanford University Medical Center,Scott T. Tagawa, MD, MS,Evan Y. Yu, MD

May 25th 2022

Reflections on results of the VISION trial, which utilized 177Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer.

Addressing Bone and Visceral Metastases in Metastatic CRPC

ByAlicia Morgans, MD, MPH, FASCO,Matthew Smith, MD, PhD,Sandy Srinivas, MD, Stanford University Medical Center,Scott T. Tagawa, MD, MS,Evan Y. Yu, MD

May 18th 2022

A broader perspective on the management of bone and visceral metastases in metastatic CRPC given the current treatment landscape.

Role of 177Lu-PSMA-617 in mCRPC and Bone Metastases

ByAlicia Morgans, MD, MPH, FASCO,Matthew Smith, MD, PhD,Sandy Srinivas, MD, Stanford University Medical Center,Scott T. Tagawa, MD, MS,Evan Y. Yu, MD

May 18th 2022

Shifting their focus to 177Lu-PSMA-617 in metastatic CRPC, expert panelists consider its role in sequencing therapy and managing bone metastases.

Selecting Among Novel Imaging Options in Metastatic CRPC

ByAlicia Morgans, MD, MPH, FASCO,Matthew Smith, MD, PhD,Sandy Srinivas, MD, Stanford University Medical Center,Scott T. Tagawa, MD, MS,Evan Y. Yu, MD

May 11th 2022

A brief discussion on how to select and apply novel imaging strategies in patients with metastatic castration-resistant prostate cancer.

Metastatic CRPC: Utility of Imaging as a Biomarker

ByAlicia Morgans, MD, MPH, FASCO,Matthew Smith, MD, PhD,Sandy Srinivas, MD, Stanford University Medical Center,Scott T. Tagawa, MD, MS,Evan Y. Yu, MD

May 11th 2022

Shared insight on the role of imaging as a phenotypic biomarker in patients being treated for metastatic castration-resistant prostate cancer.

Monitoring Strategies in Nonmetastatic CRPC

ByAlicia Morgans, MD, MPH, FASCO,Matthew Smith, MD, PhD,Sandy Srinivas, MD, Stanford University Medical Center,Scott T. Tagawa, MD, MS,Evan Y. Yu, MD

April 13th 2022

A brief discussion on best practices in monitoring patients on therapy for nonmetastatic castration-resistant prostate cancer [nmCRPC].

Nonmetastatic Castration-Resistant Prostate Cancer: Quality of Life Measures

ByAlicia Morgans, MD, MPH, FASCO,Matthew Smith, MD, PhD,Sandy Srinivas, MD, Stanford University Medical Center,Scott T. Tagawa, MD,Evan Y. Yu, MD

April 13th 2022

A brief review of the value of quality of life measures while managing patients on therapy for nonmetastatic castration-resistant prostate cancer (nmCRPC).

Treatment Advances in mCSPC

ByAlicia K. Morgans, MD, MPH, Robert H. Lurie Comprehensive Cancer Center of Northwestern University,Scott T. Tagawa, MD, MS, FACP, Weill Cornell Medicine,Sandy Srinivas, MD, Stanford University Medical Center

August 30th 2021

Treatment Advances in mCSPC

18F-DCFPyL PET/CT Imaging for Suspected Recurrent Prostate Cancer

ByAlicia K. Morgans, MD, MPH, Robert H. Lurie Comprehensive Cancer Center of Northwestern University,Sandy Srinivas, MD, Stanford University Medical Center

August 30th 2021

A discussion regarding use of the PSMA-targeted 18F-DCFPyL PET/CT to assess patients with suspected recurrence of prostate cancer based on data revealed by the CONDOR trial.

Phenotypic Biomarkers in Advanced Prostate Cancer

ByAlicia K. Morgans, MD, MPH, Robert H. Lurie Comprehensive Cancer Center of Northwestern University,Phillip J. Koo, MD,Sandy Srinivas, MD, Stanford University Medical Center

August 23rd 2021

A discussion regarding the use of PSMA PET imaging to detect phenotypic biomarkers that may simplify approaches to precision medicine in advanced prostate cancer.